We serve Chemical Name:(5-Methyl-2-phenylthiazole-4-yl)acetic acid CAS:101736-22-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(5-Methyl-2-phenylthiazole-4-yl)acetic acid
CAS.NO:101736-22-5
Synonyms:(5-Methyl-2-phenyl-1,3-thiazol-4-yl)acetic acid;(5-Methyl-2-phenylthiazole-4-yl)acetic acid;2-(3,5-DIMETHYL-PYRAZOL-1-YL)-PHENYLAMINE;MFCD00277218;(5-Methyl-2-phenyl-thiazol-4-yl)-essigsaeure;methylphenylthiazolylaceticacid;(5-methyl-2-phenyl-thiazol-4-yl)-acetic acid;4-Thiazoleacetic acid, 5-methyl-2-phenyl-;4-Thiazoleacetic acid,5-methyl-2-phenyl
Molecular Formula:C12H11NO2S
Molecular Weight:233.286
HS Code:2934100090
Physical and Chemical Properties:
Melting point:135-137ºC
Boiling point:435.1±37.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.616
PSA:78.43000
Exact Mass:233.051056
LogP:2.99
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (5-Methyl-2-phenyl-1,3-thiazol-4-yl)acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Thiazoleacetic acid,5-methyl-2-phenyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methylphenylthiazolylaceticacid Use and application,(5-Methyl-2-phenylthiazole-4-yl)acetic acid technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-7-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylic acid manufacturers In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 3-Undecene-2,5,10-trione, 9-hydroxy-6,6-dimethyl-, (E)- suppliers AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. C-Iodo-N-[1-methylamino-1-phenyl-meth-(Z)-ylidene]-methanesulfonamide vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-7-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylic acid manufacturers In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 3-Undecene-2,5,10-trione, 9-hydroxy-6,6-dimethyl-, (E)- suppliers AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. C-Iodo-N-[1-methylamino-1-phenyl-meth-(Z)-ylidene]-methanesulfonamide vendor & factory.
